COPD
Boehringer’s COPD drug passes hurdle
May 23, 2012Research and Development, Sales and Marketing Boehringer, COPD, Daxas, Relovair, Spiriva, olodaterol
Boehringer Ingelheim’s once-daily bronchodilator olodaterol has improved lung function versus placebo in a Phase II trial. The manufacturer wants the …
GSK buys more of Theravance
May 18, 2012Research and Development, Sales and Marketing COPD, Cellzome, GSK, Relovair, Theravance
GlaxoSmithKline now owns more than a quarter of biopharma company Theravance after shelling out nearly $213 million to buy ten …
ABPI launches new NHS partnership guide
May 15, 2012Medical Communications, Sales and Marketing ABPI, COPD, NHS, code
The Association of the British Pharmaceutical Industry has launched a new guide to explain how pharma and the NHS can …
Prescription drugs could become OTC under FDA plans
March 12, 2012Sales and Marketing COPD, FDA, OTC, prescribing
The FDA is considering new plans to make drugs for chronic conditions available over-the-counter. These drugs could include medicines for …
Underwhelming results for GSK’s Relovair
January 10, 2012Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma
GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …
NICE rejects Merck’s COPD drug Daxas
December 9, 2011Sales and Marketing COPD, Daxas, Merck, Nycomed
NICE has not recommended Merck’s COPD drug Daxas and is asking for a new clinical trial to test its effectiveness. …
Munro & Forster win PRCA Health and Wellbeing Award
November 28, 2011Medical Communications COPD, ERS, Munro & Forster, PRCA
Healthcare comms agency Munro & Forster has won an industry award for its innovative World Spirometry Day Campaign for the …
FDA delays decision on Novartis’ COPD drug
March 23, 2011Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol
The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Novartis’ COPD drug recommended for FDA approval
March 10, 2011Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol
Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …
Forest’s COPD drug approved in US
March 3, 2011Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast
Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …
Digital Pharma: Pfizer and Boehringer’s online COPD awareness
November 12, 2010Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease
Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …
Pfizer and Boehringer pilot COPD campaign
November 9, 2010Medical Communications Boehringer Ingelheim, COPD, Pfizer, Salford, chronic bronchitis, chronic obstructive pulmonary disease, emphysema
Pfizer and Boehringer Ingelheim have mobilised a soap opera star, painted rugby players and a special ‘breathing bus’ for a …
New COPD and asthma treatments jostle for market space
October 6, 2010Research and Development, Sales and Marketing COPD, Daxas, Onbrez Breezhaler, Revolair, asthma
Competition in the field of COPD and asthma is hotting up, with new data for several key treatments recently unveiled. …
Extra phase II studies boost GSK’s Relovair
September 23, 2010COPD, GlaxoSmithKline, Relovair, asthma
GlaxoSmithKline has conducted additional phase II trials on its asthma/COPD drug Relovair to answer a number of safety and efficacy …
Novartis hails longer-lasting COPD drug
September 20, 2010Research and Development, Sales and Marketing COPD, Novartis, Onbrez Breezhaler
A phase III treatment for COPD has demonstrated superior results over GSK’s established Serevent (salmeterol). Data from Novartis’ INSIST study …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
